Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of clinically possible or probable DLB using established criteria~* Age 50-90 inclusive~* Epworth Sleepiness Scale score of 8 or greater~* MMSE score between 10 and 26 inclusive~* No active medical disorder that could preclude participation in a drug treatment trial over a 12 week protocol~* Stable medication regimen over previous four weeks~* Absence of psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness~* Absence of clinically significant primary sleep-related breathing disorder causing sleepiness as demonstrated by polysomnography (PSG) \[ie, no significant upper airway resistance syndrome (UARS), obstructive sleep apnea (OSA), nor central sleep apnea (CSA) as reflected by a combined respiratory disturbance index (RDI) \<15\] OR adequate documentation of efficacy of treatment for UARS, OSA, and CSA~* Caregiver that is with the patient at least 4 hours/day for at least 5 days per week~* Patient and caregiver willing and able to participate in all study-related procedures~* Patient is capable of giving informed consent, or if appropriate, has caregiver capable of giving consent on the subject's behalf.~Exclusion Criteria:~* Does not fulfill criteria for clinically possible or probable DLB~* Age \<50 or \>90~* Women with intact uterus and not post-menopausal unless pregnancy test performed at screening is negative~* Epworth Sleepiness Scale score less than 8~* MMSE score \<10 or \>26~* Active medical disorder that could preclude participation in a drug treatment trial over a 52 week protocol, such as:~  * Hypertension with BP readings exceeding 150 mm Hg systolic and 90 mm Hg diastolic~ * Hypersensitivity to modafinil, armodafinil, or any other conventional stimulants~ * Myocardial infarction or cerebral infarct over preceding year, stable or unstable angina, known symptomatic coronary artery disease~ * History of left ventricular hypertrophy or mitral valve prolapse~ * History of chronic or paroxysmal atrial fibrillation, chronic or paroxysmal atrial flutter, ventricular fibrillation, or ventricular tachycardia~ * History of cancer over preceding 1 year (excluding squamous or basal cell carcinoma of the skin)~ * History of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS)~ * Pulmonary disease requiring oral or inhalatory medications~ * Any other medical disorder considered by the study physicians as inappropriate for any wake-promoting medication~* Medication regimen has not been stable over preceding four weeks~* Concurrent use of lamotrigine or oxcarbazepine~* Presence of over-the-counter and prescription psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness, such as:~  * Clonazepam \> 1 mg/night~ * Seroquel \> 100 mg/night~ * Zyprexa \> 10 mg/night~* Presence of another clinically-significant primary sleep disorder (eg, UARS, OSA, CSA) that is not being treated~* Clinically significant abnormalities on screening ECG or laboratory tests~* Patient or caregiver unwilling or unable to participate in all study-related procedures~* Caregiver is not with patient at least 4 hours/day for at least 5 days/week~* Patient or caregiver unwilling or unable to provide informed consent~* CT or MRI evidence of a clinically significant structural lesion that could account for the participants dementia

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Armodifinil (Type: OTHER): 150-250 mg armodafinil by mouth daily

Based on this trial design, predict the completion outcome and termination type (if applicable).